FBM’s Technology has the potential to favorably impact the treatment of a broad population of people across a broad spectrum of diseases, including Heart Failure, Cardiorenal Syndrome, Sepsis and Acute Kidney Injury. These patients present with a variety of symptoms and experience high hospitalization and mortality rates. More effective, timely treatment can impact morbidity and mortality rates and has the potential to reduce overall costs.
Heart Failure today costs Americans about $30 billion dollars per year, with those costs expected to rise to almost $70 billion by 2030. About 80% of those costs are due to hospitalization.
- American Heart Association
Current estimates are that nearly 6.5 million Americans over the age of 20 have heart failure. with 960,000 new heart failure cases annually. Heart Failure is the number one cause of hospitalizations in our Medicare population.
- Heart Failure Society of America
FAST Biomedical offers a direct, dynamic, serial measurement of blood volume, which can potentially give a clearer clinical picture to improve fluid management. Improved fluid management has the potential to reduce mortality rate, length of stay and readmissions.